Cargando…
Lack of pharmacokinetic interaction between derazantinib and naringin in rats
CONTEXT: Derazantinib—an orally bioavailable, ATP competitive, multikinase inhibitor—has strong activity against fibroblast growth factor receptors (FGFR)2, FGFR1, and FGFR3 kinases. It has preliminary antitumor activity in patients with unresectable or metastatic FGFR2 fusion-positive intrahepatic...
Autores principales: | Liu, Ya-nan, Chen, Jie, Xu, Xinhao, Hu, Yingying, Hu, Jin-yu, Xu, Ren-ai, Lin, Guanyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013357/ https://www.ncbi.nlm.nih.gov/pubmed/36891628 http://dx.doi.org/10.1080/13880209.2023.2185641 |
Ejemplares similares
-
Probing the Effects of the FGFR-Inhibitor Derazantinib on Vascular Development in Zebrafish Embryos
por: Kotini, Maria P., et al.
Publicado: (2020) -
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
por: Mazzaferro, Vincenzo, et al.
Publicado: (2018) -
Pharmacokinetics, Tissue Distribution, Metabolism, and Excretion of Naringin in Aged Rats
por: Zeng, Xuan, et al.
Publicado: (2019) -
Comparative Pharmacokinetics of Naringin in Rat after Oral Administration of Chaihu-Shu-Gan-San Aqueous Extract and Naringin Alone
por: Li, Shu-Qi, et al.
Publicado: (2013) -
Multi-Component Comparative Pharmacokinetics in Rats After Oral Administration of Fructus aurantii Extract, Naringin, Neohesperidin, and Naringin-Neohesperidin
por: Yuan, Jinbin, et al.
Publicado: (2020)